The performance mutation of the proposed purchase contract cited the supervision of the Shenzhen Sto 海狼行动演员表

Intends to purchase the underlying performance lead mutation regulatory attention Shenzhen inquiry Chongqing Three Gorges A hot column capital flows thousand thousand shares of stock on the latest rating diagnosis simulated trading client sina finance App: Live on-line blogger to tutor the purchase of new shares: the stock market is the most simple way to pick up the money, reporter Zhu Wen bin, editor Qiu Jiang as the latest case Chongqing state owned assets operation, Chongqing Three Gorges A intends to spend 3 billion 100 million yuan acquisition of its major shareholders held by Ningxia Chongqing purple violet 100% equity plan cause regulatory attention. 29, the Shenzhen Stock Exchange issued a letter of inquiry, Ningxia purple in a sudden burst of short-term performance of state-owned Chongqing white, and quickly became the target of trade, to question the state-owned Chongqing "golden touch". According to the plan, Ningxia violet was founded in June 2013, the main business income of 24 million yuan in 2014, the loss of 16 million yuan in the year. The performance of the turning point occurred in January 2015, when the controlling shareholder of Chongqing Three Gorges A medical group through capital 213 million yuan to become the largest shareholder of Chongqing purple, violet in Chongqing are therefore included in the state-owned Chongqing territory. In the same year, Ningxia purple performance has increased dramatically, the main business revenue soared to 1 billion 137 million yuan, net profit increased to 254 million yuan. From January 2016 to July, the main business income and net profit of Ningxia violet were 660 million yuan and 153 million yuan respectively. In this transaction, Ningxia violet estimated value of 3 billion 93 million yuan, the estimated value added rate of 347.99%. For the Chongqing state so terrible, because the "golden touch" Shenzhen enquiry requirements of listed companies of Ningxia violet sharp fluctuations in short-term performance for supplement, the basic situation, and detailed disclosure of the evaluation value range, assessment assumptions, assessment process, parameter selection and its basis. The concern is Ningxia violet in the medical group entered the two capital Chongqing violet obtained before and after, which in December 2014 was Chongqing violet capital 200 million yuan, in April 2015 by the Ningbo Xing Sheng capital 600 million yuan. In April 2016, Ningxia purple of Ningbo Xing Sheng of equity repurchase and capital reduction. Due to the restructuring plan of Chongqing Three Gorges A did not disclose the transaction price per unit, the Shenzhen Stock Exchange therefore require the company to compare the price and unit price disclosure of the transaction, and explains the difference. At the same time, feedback the Shenzhen Stock Exchange after the review, require the company to block or other effective forms, full disclosure of the counterparty of property right and control relation, property relation between structure of indirect control include major shareholders or other holders of equity trading, equity or equity and each layer, some kind of agreement or other institutions the arrangements reached between until the natural person, the state-owned assets management departments or shareholders. Ningxia purple light follow-up earnings also attracted the attention of the Shenzhen stock exchange. According to Chongqing Three Gorges A restructuring plan, Chongqing from 2017 to 2019 Ningxia violet violet commitments net profit after deduction of non were not less than 340 million 170 thousand yuan, 379 million 920 thousand yuan, 407 million 790 thousand yuan. The Shenzhen stock exchange requires the company to disclose the above results with the current overcapacity situation in the methionine industry

拟购标的业绩突变引监管关注 深交所问询渝三峡A 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 新股申购:股市最简单捡钱方式   ⊙记者 朱文彬 ○编辑 邱江   作为重庆国资运作的最新案例,渝三峡A拟斥资31亿元收购大股东旗下重庆紫光所持宁夏紫光100%股权的预案引起监管关注。29日,深交所发出问询函,就宁夏紫光在重庆国资入主后短期内业绩突然爆发,并迅速成为此次交易的标的,对重庆国资的“点金术”提出疑问。   根据预案,宁夏紫光成立于2013年6月,2014年主营业务收入2400万元,当年亏损1600万元。其业绩转折点发生在2015年1月,彼时,渝三峡A控股股东化医集团通过增资2.13亿元成为重庆紫光的大股东,重庆紫光因此被纳入重庆国资的版图。当年,宁夏紫光业绩便出现大幅提升,主营业务收入飙升至11.37亿元,净利润增至2.54亿元。2016年1月至7月,宁夏紫光主营业务收入和净利润分别为6.6亿元1.53亿元。在此次交易中,宁夏紫光预估值为30.93亿元,预估增值率为347.99%。   对于重庆国资如此了得的“点金术”,深交所问询函要求上市公司对宁夏紫光短期内业绩大幅波动的原因进行补充说明,并详细披露此次评估的基本情况、增值幅度、评估假设、评估过程、参数选择及其依据。   值得关注的是宁夏紫光在化医集团入主重庆紫光前后获得的两次增资,其中2014年12月获重庆紫光增资2亿元,2015年4月获宁波兴晟增资6亿元。而在2016年4月,宁夏紫光又对宁波兴晟进行了股权回购并减资。由于渝三峡A的重组预案并未披露上述交易的单位价格,深交所因此要求公司披露该价格与此次交易的单位价格进行对比,并就差异进行说明。   与此同时,深交所在事后审查的反馈意见中,要求公司以方框图或者其他有效形式,全面披露交易对方相关的产权及控制关系,包括交易对方的主要股东或权益持有人、股权或权益的间接控制人及各层之间的产权关系结构图,直至自然人、国有资产管理部门或者股东之间达成某种协议或安排的其他机构。   宁夏紫光的后续盈利也引起深交所关注。据渝三峡A重组预案,重庆紫光承诺2017年至2019年宁夏紫光扣非后净利润分别不低于34017 万元、37992万元、40779万元。深交所要求公司结合目前蛋氨酸行业产能过剩情况,补充披露上述业绩承诺的预测基础及其合理性。   此外,宁夏紫光目前拥有的《排污许可证》和《中华人民共和国海关报关单位注册登记证书》,将先后在2016年9月22日和2016年12月17日到期。对于其主要资质证书若到期后未能获得顺利续展而面临无法正常开展业务的风险,深交所要求公司补充披露相关信息。   深交所还关注到,宁波兴晟对宁夏紫光的增资、减资行为实际上属于“名股实债”的情形,以及报告期内宁夏紫光与控股股东重庆紫光之间存在金额较大的关联交易,宁夏紫光还有部分房产尚未办理产权程序、处于抵押状态等多种情形,需要渝三峡A进一步补充披露相关信息。 进入【新浪财经股吧】讨论相关的主题文章: